By Jeff Buchanan, Xconomy
The Madison, WI-based company’s flagship product, called Excelsior, is a cloud-based software-as-a-service (SaaS) platform that helps researchers collect and interpret ophthalmic data. Excelsior, which in 2013received 510(k) clearance from the FDA, is specifically designed for image and data management in trials of drug candidates aimed at treating ocular diseases.
Gary Leatherberry, EyeKor’s chief operating officer, says that his company plans to use some of the money “to make key hires, accelerate the development of our software platform, and expand commercial opportunities.”
EyeKor, which seeks to sell to pharmaceutical companies and contract research organizations, also plans to obtain FDA clearance for “additional features” of its digital tools, Leatherberry says.